MicroRNA-4463 facilitates the development of colon cancer by suppression of the expression of PPP1R12B

Tan, Jun; Lu, Ting; Xu, Junhua; Hou, Yaxin; Chen, Z.; Zhou, Kaiyu; Ding, Ye; Jiang, Bin; Zhu, Yongjia

doi:10.1007/s12094-021-02752-0

Cited by 5 publications

(3 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MicroRNAs (miRNAs) are another important class of regulatory non‐coding RNAs of ∼22 nts in length, and their roles in disease have been studied extensively in the past decade 11 . In CRC, for example, miR‐4463 acts as an oncogene by promoting the progression of CRC via regulation of the PPP1R12B gene 12 . It has also been proposed that upregulation of miR‐582‐5p expression could inhibit migration and chemotherapy drug resistance of CRC cells 13 .…”

Section: Introductionmentioning

confidence: 99%

“…11 In CRC, for example, miR-4463 acts as an oncogene by promoting the progression of CRC via regulation of the PPP1R12B gene. 12 It has also been proposed that upregulation of miR-582-5p expression could inhibit migration and chemotherapy drug resistance of CRC cells. 13 Conversely, several studies have suggested that miR-506-3p expression is remarkably lower in CRC cells than in normal cells, suggesting a role as a tumor suppressor in the progression of CRC.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Circ‐MALAT1 accelerates cell proliferation and epithelial mesenchymal transformation of colorectal cancer through regulating miR‐506‐3p/KAT6B axis

Yang,

Gong,

Qiu

2023

The Kaohsiung J of Med Scie

View full text Add to dashboard Cite

Colorectal cancer (CRC) is a prevalent malignant tumor of the digestive tract. Circular RNAs may play important roles in the progression of CRC. In this study, we investigated the roles and mechanisms of action of circ‐MALAT1 in CRC. Gene expression and protein abundance were determined using qRT‐PCR and western blot, respectively. Cell proliferation and migration were assessed by MTT, clone formation, and wound‐healing assays. The interactions among the long non‐coding RNA metastasis‐associated lung adenocarcinoma transcript 1 (circ‐MALAT1), miR‐506‐3p, and lysine acetyltransferase 6B (KAT6B) were predicted using the StarBase software and confirmed by the luciferase activity assay. Circ‐MALAT1 and KAT6B were upregulated, while miR‐506‐3p was downregulated in CRC cells. We validated that knocking down of circ‐MALAT1 suppressed proliferation, migration, and epithelial–mesenchymal transition (EMT) of CRC cells, and these effects were abolished by miR‐506‐3p downregulation or KAT6B sufficiency. Our study suggests that circ‐MALAT1 could sponge miR‐506‐3p to regulate the expression of KAT6B. Moreover, KAT6B sufficiency could neutralize miR‐506‐3p‐dependent growth arrest, migration, and EMT. Circ‐MALAT1 promotes cell proliferation, migration, and EMT of CRC cells via the miR‐506‐3p/KAT6B axis, thereby acting as a novel potential therapeutic target for the treatment of colorectal cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

mentioning

confidence: 99%

Circ‐MALAT1 accelerates cell proliferation and epithelial mesenchymal transformation of colorectal cancer through regulating miR‐506‐3p/KAT6B axis

Yang,

Gong,

Qiu

2023

The Kaohsiung J of Med Scie

View full text Add to dashboard Cite

show abstract

“…PPP1R12B contains a terminal leucine zipper and is involved in dimerization and protein-protein interaction (62). In colon cancer, PPP1R12B promotes proliferation, migration, inhibits apoptosis and up-regulates phosphatidylinosite-3-kinase (PI3K)/AKT signaling (63,64).…”

Section: Circ Homeodomain-interacting Protein Kinase 2 (Circhipk2) Up...mentioning

confidence: 99%

Deregulated circRNAs in Epithelial Ovarian Cancer With Activity in PreclinicalIn VivoModels: Identification of Targets and New Modalities for Therapeutic Intervention

WEIDLE,

BIRZELE

2024

Cancer Genomics Proteomics

View full text Add to dashboard Cite

Epithelial ovarian cancer (EOC) is associatedwith a dismal prognosis due to development of resistance to chemotherapy and metastasis in the peritoneal cavity and distant organs. In order to identify new targets and treatment modalities we searched the literature for up-and and downregulated circRNAs with efficacy in preclinical EOC-related in vivo systems. Our search yielded circRNAs falling into the following categories: cisplatin and paclitaxel resistance, transmembrane receptors, secreted factors, transcription factors, RNA splicing and processing factors, RAS pathwayrelated components, proteolysis and cell-cycle regulation, signaling-related proteins, and circRNAs regulating proteins in additional categories. These findings can be potentially translated by validation and manipulation of the corresponding targets, inhibition of circRNAs with antisense oligonucleotides (ASO), small interfering RNAs (siRNA) or small hairpin RNA (shRNA) or by reconstituting their activity.The incidence of ovarian cancer (OC) in the USA is 22,000 cases per year and 14,000 deaths, and 29,000 deaths in Europe (1). The vast majority are epithelial ovarian cancers (EOC). This type of tumor is typically treated with a combination of surgery and chemotherapy, which often includes cisplatin (DDP) and paclitaxel (PTX). An exciting development was the treatment of homologous recombination-deficient ovarian tumors with breast cancer antigen (BRCA) mutations or deletions with poly-ADP-ribose polymerase (PARP) inhibitors (2). Three PARP inhibitors (olaparib, rucaparib and niraparib) have been approved for the treatment of OCs in different clinical settings. In addition, anti-angiogenic therapy with Bevacizumab was approved (3). Nevertheless, recurrence due to resistance mechanisms is commonly observed and significantly impairs the therapeutic benefit of treatment (4). Epithelial ovarian cancer (EOC) gains a growth advantage due to interactions with fat cells, mesothelial cells, and cancerassociated fibroblasts. These interactions enhance the activation of pathways that support its growth (5-7). Also, its dissemination in ascites fluid and formation of nodules in the peritoneum are a unique mechanism of metastasis hampering therapeutic intervention (8, 9). Immunotherapy with checkpoint inhibitors such as Pembrolizumab has shown limited success (10). Diverse mechanisms of immune escape in a tumorlocation specific manner have been observed (11). Taken together, there is a tremendous medical need for identification of new targets and modalities for treatment of OC. Therefore, we searched the literature for circular RNAs (circRNAs) that are up-or down-regulated in EOC and upon their modulation exhibit efficacy in preclinical in vivo models of EOC. Circular RNA in CancercircRNA can be generated during mRNA processing by intramolecular mRNA pairing followed by circularization, RNA-213

show abstract

Integrating transcriptomics and proteomics to analyze the immune microenvironment of cytomegalovirus associated ulcerative colitis and identify relevant biomarkers

Chen,

Zheng,

Wang

et al. 2024

BioData Mining

View full text Add to dashboard Cite

MicroRNA-4463 facilitates the development of colon cancer by suppression of the expression of PPP1R12B

Cited by 5 publications

References 35 publications

Circ‐MALAT1 accelerates cell proliferation and epithelial mesenchymal transformation of colorectal cancer through regulating miR‐506‐3p/KAT6B axis

Circ‐MALAT1 accelerates cell proliferation and epithelial mesenchymal transformation of colorectal cancer through regulating miR‐506‐3p/KAT6B axis

Deregulated circRNAs in Epithelial Ovarian Cancer With Activity in PreclinicalIn VivoModels: Identification of Targets and New Modalities for Therapeutic Intervention

Integrating transcriptomics and proteomics to analyze the immune microenvironment of cytomegalovirus associated ulcerative colitis and identify relevant biomarkers

Contact Info

Product

Resources

About